XML 37 R17.htm IDEA: XBRL DOCUMENT
v3.22.2.2

INFORMATION ABOUT COMPONENTS OF EQUITY | 12 Months Ended
--- | ---
Jun. 30, 2022
INFORMATION ABOUT COMPONENTS OF EQUITY |
INFORMATION ABOUT COMPONENTS OF EQUITY | 11. INFORMATION ABOUT COMPONENTS OF EQUITY Capital issued As of June 30, 2022, we had, (i) 100,000,000 ordinary shares ($0.0001 par value) authorized, (ii) 46,334,801 ordinary shares issued and outstanding, (iii) 1,000,000 preference shares ($0.0001 par value) authorized, (iv) no preference shares issued and outstanding, (v) 1,883,314 ordinary shares reserved for our equity compensation plans. Of the total issued shares we have repurchased 464,455 shares of our own. Holders of the ordinary shares are entitled to one vote for each ordinary share. Convertible notes Convertibles notes were classified as compound instruments, a non-derivative financial instrument that contains both a liability and an equity component. The equity consideration was included in the “Convertible instruments” column. See Note 7.17 Non-controlling interests The subsidiary whose non-controlling interest is significant as of June 30, 2022, 2021 and 2020 is: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Name |  | 06/30/2022 |  | 06/30/2021 |  | 06/30/2020 | ​
Rizobacter Argentina S.A. | ​ | 20 | % | 20 | % | 20 | %
Insumos Agroquimicos S.A. | ​ | 38.68 | % | 49.9 | % | — | ​
​ Below is a detail of the summarized financial information of Rizobacter and Insuagro, prepared in accordance with IFRS, and modified due to fair value adjustments at the acquisition date and differences in accounting policies. The information is presented prior to eliminations between that subsidiary and other Group companies. Rizobacter ​
​ | ​ | ​ | ​ | ​ | ​ | ​
Summary financial statements: |  | 06/30/2022 |  | 06/30/2021 |  | 06/30/2020
Current assets |  | 294,372,669 |  | 175,906,282 |  | 148,256,827
Non-current assets |  | 77,663,085 |  | 59,860,206 |  | 49,843,457
Total assets |  | 372,035,754 |  | 235,766,488 |  | 198,100,284
​ | ​ | ​ | ​ | ​ | ​ | ​
Current liabilities |  | 181,999,148 |  | 120,036,912 |  | 129,838,941
Non-current liabilities |  | 98,070,280 |  | 57,480,984 |  | 32,935,399
Total liabilities |  | 280,069,428 |  | 177,517,896 |  | 162,774,340
​ | ​ | ​ | ​ | ​ | ​ | ​
Equity attributable to controlling interest |  | 91,965,153 |  | 58,246,057 |  | 35,324,227
Equity attributable to non-controlling interest |  | 1,173 |  | 2,535 |  | 1,717
Total equity |  | 91,966,326 |  | 58,248,592 |  | 35,325,944
​ | ​ | ​ | ​ | ​ | ​ | ​
Total liabilities and equity |  | 372,035,754 |  | 235,766,488 |  | 198,100,284
​ ​
​ | ​ | ​ | ​ | ​ | ​ | ​
Summary statements of comprehensive income or loss |  | 06/30/2022 |  | 06/30/2021 |  | 06/30/2020
Revenues |  | 280,625,028 | ​ | 189,749,478 | ​ | 162,404,866
Initial recognition and changes in the fair value of biological assets at the point of harvest |  | 3,973,780 | ​ | 1,552,746 | ​ | 716,741
Cost of sales | ​ | (176,497,573) | ​ | (106,636,141) | ​ | (86,533,561)
Gross margin |  | 108,101,235 | ​ | 84,666,083 | ​ | 76,588,046
​ | ​ | ​ | ​ | ​ | ​ | ​
Research and development expenses |  | (3,190,439) | ​ | (3,208,904) | ​ | (2,689,468)
Selling, general and administrative expenses |  | (59,057,350) | ​ | (37,500,952) | ​ | (36,103,289)
Share of profit or loss of joint ventures and associates |  | 611,989 | ​ | 481,442 | ​ | 1,960,549
Other income |  | 113,378 | ​ | 507,246 | ​ | (380,871)
Operating profit |  | 46,578,813 | ​ | 44,944,915 | ​ | 39,374,967
​ | ​ | ​ | ​ | ​ | ​ | ​
Financial results |  | (12,668,145) | ​ | (11,032,748) | ​ | (30,014,131)
Profit before taxes |  | 33,910,668 | ​ | 33,912,167 | ​ | 9,360,836
​ | ​ | ​ | ​ | ​ | ​ | ​
Income tax expense |  | (16,788,853) | ​ | (14,141,515) | ​ | (3,830,106)
Result for the year |  | 17,121,815 | ​ | 19,770,652 | ​ | 5,530,730
​ | ​ | ​ | ​ | ​ | ​ | ​
Foreign exchange differences on translation of foreign operations |  | 1,824,666 | ​ | 1,704,590 | ​ | 1,281,974
Revaluation of property, plant and equipment, net of tax |  | (5,308,610) | ​ | (2,682,457) | ​ | 3,921,091
Total comprehensive result |  | 13,637,871 | ​ | 18,792,785 | ​ | 10,733,795
​ There were no dividends paid to Rizobacter non-controlling interest (NCI) in the years ended June 30, 2022, 2021 and 2020. Insuagro ​
​ | ​ | ​ | ​ | ​
​ |  | 06/30/2022 |  | 06/30/2021
Current assets |  | 40,361,614 |  | 23,293,521
Non-current assets |  | 2,295,965 |  | 2,907,928
Total assets |  | 42,657,579 |  | 26,201,449
​ | ​ | ​ | ​ | ​
Current liabilities |  | 35,464,893 |  | 20,297,799
Non-current liabilities |  | 118,460 |  | 1,341,613
Total liabilities |  | 35,583,353 |  | 21,639,412
​ | ​ | ​ | ​ | ​
Total equity |  | 7,074,226 |  | 4,562,037
​ | ​ | ​ | ​ | ​
Total liabilities and equity |  | 42,657,579 |  | 26,201,449
​ ​
​ | ​ | ​ | ​ | ​
Summary statements of comprehensive income or loss (1) |  | 06/30/2022 |  | 06/30/2021
Revenues | ​ | 49,116,626 | ​ | 7,600,041
Cost of sales | ​ | (35,181,813) | ​ | (5,886,326)
Gross margin | ​ | 13,934,813 | ​ | 1,713,715
​ | ​ | ​ | ​ | ​
Selling, general and administrative expenses | ​ | (7,894,444) | ​ | (1,065,147)
Other income or expenses, net | ​ | 159,794 | ​ | 18,305
Operating profit | ​ | 6,200,163 | ​ | 666,873
​ | ​ | ​ | ​ | ​
Financial results | ​ | (2,954,581) | ​ | (961,635)
Profit/(loss) before tax | ​ | 3,245,582 | ​ | (294,762)
Income tax | ​ | (1,421,973) | ​ | 127,876
Profit/(loss) for the year | ​ | 1,823,609 | ​ | (166,886)
​ | ​ | ​ | ​ | ​
Exchange differences on translation of foreign operations | ​ | 733,029 | ​ | 180,519
Total comprehensive result | ​ | 2,556,638 | ​ | 13,633
​
(1) | For the year ended June 30, 2021, the results are from 9 April 2021, the date of the acquisition of Insuagro. See Note 6.

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfClassesOfShareCapitalAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for share capital, reserves and other equity interest. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 79 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration